55289-36-6Relevant articles and documents
Single-atom Fe-N4site for the hydrogenation of nitrobenzene: theoretical and experimental studies
Dong, Panpan,He, Rong,Liu, Yan,Lu, Ning,Mao, Junjie,Wu, Konglin,Zhang, Wenzhuang,Zheng, Yamin
supporting information, p. 7995 - 8001 (2021/06/21)
The hydrogenation of nitrobenzene to aniline is an important process in the industry of fine chemicals, but developing inexpensive catalysts with expected activity and selectivity still remains a challenge. By using density functional theory calculations, we demonstrated that the isolated Fe atom not only can weaken the adsorption of reactants and reaction intermediates as compared to Fe nanoparticles, but also remarkably decrease the reaction barrier for the hydrogenation of nitrobenzene to aniline. Thus, the Fe single-atom (Fe SA) catalyst is considered as an ideal catalyst for this reaction. This theoretical prediction has been subsequently confirmed by experimental results obtained for the Fe SAs loaded on N-doped hollow carbon spheres (Fe SAs/NHCSs) which achieved a conversion of 99% with a selectivity of 99% for the hydrogenation of nitrobenzene. The results significantly outperformed the Fe nanoparticles for this reaction. This work provides theoretical insight for the rational design of new catalytic systems with excellent catalytic properties.
NOVEL IRREVERSIBLE BRUTON'S TYROSINE KINASE INHIBITOR
-
Paragraph 0104; 0108, (2019/01/04)
The present invention provides an inhibitor of Bruton's tyrosine kinase, which is a compound of formula (I), or its pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug. The present invention also provides a pharmaceutical composition comprsing the compound. The present invention also provides a method for inhibiting the activity of tyrosine kinase activity or for treating a disease, disorder, or condition, which would benefit from the inhibition of Bruton's tyrosine kinase(s), by using the Bruton's tyrosine kinase inhibitor, as well as application of the Bruton's tyrosine kinase inhibitor for the same.
Synthesis and Antibacterial Activity of Novel 4-Bromo-1H-Indazole Derivatives as FtsZ Inhibitors
Wang, Yi,Yan, Mi,Ma, Ruixin,Ma, Shutao
, p. 266 - 274 (2015/04/14)
A series of novel 4-bromo-1H-indazole derivatives as filamentous temperature-sensitive protein Z (FtsZ) inhibitors were designed, synthesized, and assayed for their in vitro antibacterial activity against various phenotypes of Gram-positive and Gram-negative bacteria and their cell division inhibitory activity. The results indicated that this series showed better antibacterial activity against Staphylococcus epidermidis and penicillin-susceptible Streptococcus pyogenes than the other tested strains. Among them, compounds 12 and 18 exhibited 256-fold and 256-fold more potent activity than 3-methoxybenzamide (3-MBA) against penicillin-resistant Staphylococcus aureus, and compound 18 showed 64-fold better activity than 3-MBA but 4-fold weaker activity than ciprofloxacin in the inhibition of S. aureus ATCC29213. Particularly, compound 9 presented the best activity (4 μg/mL) against S. pyogenes PS, being 32-fold, 32-fold, and 2-fold more active than 3-MBA, curcumin, and ciprofloxacin, respectively, but it was four times less active than oxacillin sodium. In addition, some synthesized compounds displayed moderate inhibition of cell division against S. aureus ATCC25923, Escherichia coli ATCC25922, and Pseudomonas aeruginosa ATCC27853, sharing a minimum cell division concentration of 128 μg/mL.
